MBX Biosciences, Inc Common Stock

Yahoo Finance • 12 hours ago

MBX Biosciences Announces Pricing of Upsized Public Offering

CARMEL, Ind., Sept. 24, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine... Full story

Yahoo Finance • 2 days ago

Microbix Assisting EMQN with Second Genetic-Test EQA Program

MISSISSAUGA, Ontario and MANCHESTER, United Kingdom, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, and EMQN CIC (EMQN), a global su... Full story

Yahoo Finance • 3 days ago

Stock Indexes Post New Record Highs on AI Optimism

The S&P 500 Index ($SPX [https://www.barchart.com/futures/quotes/$SPX/overview]) (SPY [https://www.barchart.com/etfs-funds/quotes/SPY/overview]) on Monday closed up +0.44%, the Dow Jones Industrials Index ($DOWI [https://www.barchart.com/f... Full story

Yahoo Finance • 3 days ago

MBX Biosciences files for public offering of 10M shares

* MBX Biosciences (NASDAQ:MBX [https://seekingalpha.com/symbol/MBX]) has fileded a proposed public offering of 10M shares of common stock. * The company also plans to grant underwriters a 30-day option to purchase up to 1.5M additional... Full story

Yahoo Finance • 3 days ago

MBX Biosciences Announces Proposed Public Offering

CARMEL, Ind., Sept. 22, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine... Full story

Yahoo Finance • 3 days ago

Stocks Supported as Chip Makers and AI-Infrastructure Companies Rally

The S&P 500 Index ($SPX [https://www.barchart.com/futures/quotes/$SPX/overview]) (SPY [https://www.barchart.com/etfs-funds/quotes/SPY/overview]) today is up +0.18%, the Dow Jones Industrials Index ($DOWI [https://www.barchart.com/futures/q... Full story

Yahoo Finance • 3 days ago

Invesco 500 Momentum ETF declares quarterly distribution of $0.1917

* Invesco 500 Momentum ETF (NYSEARCA:SPMO [https://seekingalpha.com/symbol/SPMO]) - $0.1917 [https://www.invesco.com/us/financial-products/etfs/product-detail?audienceType=Advisor&productId=ETF-SPMO]. * 30-Day SEC Yield of 0.75% as of... Full story

Yahoo Finance • 3 days ago

Stock Indexes Consolidate Below Last Week's Record Highs

The S&P 500 Index ($SPX [https://www.barchart.com/futures/quotes/$SPX/overview]) (SPY [https://www.barchart.com/etfs-funds/quotes/SPY/overview]) today is down -0.18%, the Dow Jones Industrials Index ($DOWI [https://www.barchart.com/futures... Full story

Yahoo Finance • 3 days ago

MBX Biosciences Announces Once-Weekly Canvuparatide Achieved Primary Endpoint in Phase 2 Trial with 63% Responder Rate at 12 Weeks; 79% Responder Rate at 6 Months in Open-Label Extension

Statistically significant responder rate achieved at 12 weeks with zero contribution from rescue therapy (PRN) and further improvement sustained in open-label extension (OLE) Positive findings in bone and kidney biomarkers All patients c... Full story

Yahoo Finance • 6 days ago

MBX Biosciences to Provide Topline Results from its Phase 2 Trial of Potential Once-Weekly Canvuparatide for Hypoparathyroidism (HP) on Monday, September 22

CARMEL, Ind., Sept. 19, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine... Full story

Yahoo Finance • 8 days ago

Microbix Client Labquality Introduces Novel EQA Scheme at ESCV

MISSISSAUGA, Ontario and HELSINKI, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, and Labquality Oy (Labquality), announce a novel e... Full story

Yahoo Finance • 12 days ago

SA Asks: Which biotechs could be acquired by year's end?

[word m and a made with wood building blocks, stock image] Maksim Labkouski The fourth quarter has historically been a busy time for the biopharma industry, with the sector generally seeing a significant uptick in M&A activity. We asked... Full story

Yahoo Finance • 21 days ago

MBX Biosciences Doses First Participant in Phase 1 Trial of MBX 4291 for the Treatment of Obesity

CARMEL, Ind., Sept. 04, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine... Full story

Yahoo Finance • 22 days ago

Microbix Hosts Ontario Minister Stephen Crawford

MISSISSAUGA, Ontario, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces its hosting of the Honourable Stephen Crawford, Ontar... Full story

Yahoo Finance • 2 months ago

Microbix Launches QUANTDx™ Characterized Reference Materials

MISSISSAUGA, Ontario, July 29, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces the commercial launch of QUANTDx™, a new product line... Full story

Yahoo Finance • 2 months ago

Oppenheimer initiates MBX Biosciences stock with Outperform rating

Investing.com - Oppenheimer initiated coverage on MBX Biosciences Inc (NASDAQ:MBX) with an Outperform rating and a price target of $38.00 on Wednesday. The target represents significant upside potential, with analyst targets ranging from... Full story

Yahoo Finance • 2 months ago

MBX Biosciences stock maintains Market Outperform rating at JMP

Investing.com - MBX Biosciences Inc (NASDAQ:MBX), currently trading at $13.40, maintained its Market Outperform rating and $38.00 price target from JMP Securities, which cited positive industry developments in the hypoparathyroidism (hyp... Full story

Yahoo Finance • 3 months ago

MBX Biosciences stock maintains Market Outperform rating at JMP on strong Yorvipath launch

Investing.com - JMP Securities has reiterated its Market Outperform rating and $38.00 price target on MBX Biosciences Inc (NASDAQ:MBX), citing the strong U.S. launch of the company’s Yorvipath treatment. The target represents significant... Full story

Yahoo Finance • 3 months ago

MBX Biosciences submits IND for once-monthly obesity treatment

CARMEL, Ind. - MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company with a market capitalization of $347 million, has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administratio... Full story

Yahoo Finance • 4 months ago

MBX Biosciences to Present at the American Diabetes Association 85th Scientific Sessions

CARMEL, Ind., June 10, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine... Full story